2014年生物制药基准 - Suppr

Biopharmaceutical benchmarks 2014.

作者信息

Walsh Gary

机构信息

the Industrial Biochemistry Program, Department of Chemical and Environmental Sciences, University of Limerick, Ireland, and the Materials and Surface Science Institute, University of Limerick, Ireland.

出版信息

Nat Biotechnol. 2014 Oct;32(10):992-1000. doi: 10.1038/nbt.3040.

DOI:10.1038/nbt.3040

PMID:25299917

Abstract

摘要

相似文献

Biopharmaceutical benchmarks 2014.

Nat Biotechnol. 2014 Oct;32(10):992-1000. doi: 10.1038/nbt.3040.

Biopharmaceutical benchmarks 2018.

Nat Biotechnol. 2018 Dec 6;36(12):1136-1145. doi: 10.1038/nbt.4305.

Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry.

MAbs. 2013 Sep-Oct;5(5):621-3. doi: 10.4161/mabs.25864. Epub 2013 Jul 24.

Trends in capacity utilization for therapeutic monoclonal antibody production.

MAbs. 2009 Mar-Apr;1(2):151-6. doi: 10.4161/mabs.1.2.7802. Epub 2009 Mar 8.

Maintaining 'standards' for biosimilar monoclonal antibodies.

Nat Biotechnol. 2021 Mar;39(3):276-280. doi: 10.1038/s41587-021-00848-0.

Study critiques corporate control of trials.

Nat Biotechnol. 2002 Dec;20(12):1180. doi: 10.1038/nbt1202-1180.

An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?

MAbs. 2020 Jan-Dec;12(1):1743517. doi: 10.1080/19420862.2020.1743517.

Biopharmaceutical benchmarks--2003.

Nat Biotechnol. 2003 Aug;21(8):865-70. doi: 10.1038/nbt0803-865.

J Natl Cancer Inst. 2015 Jul 3;107(7). doi: 10.1093/jnci/djv191. Print 2015 Jul.

The state of biopharmaceutical manufacturing.

Biotechnol Annu Rev. 2003;9:285-302. doi: 10.1016/s1387-2656(03)09008-2.

引用本文的文献

Unravelling fungal genome editing revolution: pathological and biotechnological application aspects.

Arch Microbiol. 2025 May 22;207(7):150. doi: 10.1007/s00203-025-04360-w.

Development of Recombinant Follicle-Stimulating Hormone for the Superovulation of Cattle: A Review.

Vet Sci. 2025 Mar 12;12(3):264. doi: 10.3390/vetsci12030264.

Construction of a TAT-Cas9-EGFP Site-Specific Integration Eukaryotic Cell Line Using Efficient PEG10 Modification.

Int J Mol Sci. 2025 Feb 4;26(3):1331. doi: 10.3390/ijms26031331.

Beyond , Pharmaceutical Molecule Production in Cell-Free Systems and the Use of Noncanonical Amino Acids Therein.

Chem Rev. 2025 Feb 12;125(3):1303-1331. doi: 10.1021/acs.chemrev.4c00126. Epub 2025 Jan 22.

The 'Omics Revolution in CHO Biology: Roadmap to Improved CHO Productivity.

Methods Mol Biol. 2025;2853:119-137. doi: 10.1007/978-1-0716-4104-0_9.

Recombinant lactate-assimilating cyanobacteria reduce high-concentration culture-associated cytotoxicity in mammalian cells.

Arch Microbiol. 2024 Oct 3;206(11):425. doi: 10.1007/s00203-024-04149-3.

The United States Food and Drug Administration's Platform Technology Designation to Expedite the Development of Drugs.

Pharmaceutics. 2024 Jul 10;16(7):918. doi: 10.3390/pharmaceutics16070918.

Comparative Analysis of the Impact of Protein on Virus Retention for Different Virus Removal Filters.

Membranes (Basel). 2024 Jul 17;14(7):158. doi: 10.3390/membranes14070158.

Recombinant CHO Cell Pool Generation Using PiggyBac Transposon System.

Methods Mol Biol. 2024;2810:137-146. doi: 10.1007/978-1-0716-3878-1_9.

RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin-RGD interactions.

Cancer Med. 2024 Jan;13(2):e6800. doi: 10.1002/cam4.6800.

本文引用的文献

The special case of gene therapy pricing.

Nat Biotechnol. 2014 Sep;32(9):874-6. doi: 10.1038/nbt.3003.

Sanofi to propel inhalable insulin Afrezza into market.

Nat Biotechnol. 2014 Sep;32(9):851-2. doi: 10.1038/nbt0914-851a.

Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.

Nature. 2014 Oct 2;514(7520):47-53. doi: 10.1038/nature13777. Epub 2014 Aug 29.

Antibody-drug conjugates: current status and future directions.

Drug Discov Today. 2014 Jul;19(7):869-81. doi: 10.1016/j.drudis.2013.11.004. Epub 2013 Nov 15.

Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry.

MAbs. 2013 Sep-Oct;5(5):621-3. doi: 10.4161/mabs.25864. Epub 2013 Jul 24.

Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.

Adv Drug Deliv Rev. 2013 Jun 15;65(6):782-99. doi: 10.1016/j.addr.2012.10.005. Epub 2012 Oct 23.

Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques.

Proc Natl Acad Sci U S A. 2012 Oct 30;109(44):18030-5. doi: 10.1073/pnas.1213709109. Epub 2012 Oct 15.

Biopharmaceutical benchmarks 2010.

Nat Biotechnol. 2010 Sep;28(9):917-24. doi: 10.1038/nbt0910-917.

Single-batch production of recombinant human polyclonal antibodies.

Mol Biotechnol. 2010 Jul;45(3):257-66. doi: 10.1007/s12033-010-9270-9.

Biopharmaceutical benchmarks 2006.

Nat Biotechnol. 2006 Jul;24(7):769-76. doi: 10.1038/nbt0706-769.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Biopharmaceutical benchmarks 2014.

Nat Biotechnol. 2014 Oct;32(10):992-1000. doi: 10.1038/nbt.3040.

Biopharmaceutical benchmarks 2018.

Nat Biotechnol. 2018 Dec 6;36(12):1136-1145. doi: 10.1038/nbt.4305.

Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry.

MAbs. 2013 Sep-Oct;5(5):621-3. doi: 10.4161/mabs.25864. Epub 2013 Jul 24.

Trends in capacity utilization for therapeutic monoclonal antibody production.

MAbs. 2009 Mar-Apr;1(2):151-6. doi: 10.4161/mabs.1.2.7802. Epub 2009 Mar 8.

Maintaining 'standards' for biosimilar monoclonal antibodies.

Nat Biotechnol. 2021 Mar;39(3):276-280. doi: 10.1038/s41587-021-00848-0.

Study critiques corporate control of trials.

Nat Biotechnol. 2002 Dec;20(12):1180. doi: 10.1038/nbt1202-1180.

An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?

MAbs. 2020 Jan-Dec;12(1):1743517. doi: 10.1080/19420862.2020.1743517.

Biopharmaceutical benchmarks--2003.

Nat Biotechnol. 2003 Aug;21(8):865-70. doi: 10.1038/nbt0803-865.

J Natl Cancer Inst. 2015 Jul 3;107(7). doi: 10.1093/jnci/djv191. Print 2015 Jul.

The state of biopharmaceutical manufacturing.

Biotechnol Annu Rev. 2003;9:285-302. doi: 10.1016/s1387-2656(03)09008-2.

引用本文的文献

Unravelling fungal genome editing revolution: pathological and biotechnological application aspects.

Arch Microbiol. 2025 May 22;207(7):150. doi: 10.1007/s00203-025-04360-w.

Development of Recombinant Follicle-Stimulating Hormone for the Superovulation of Cattle: A Review.

Vet Sci. 2025 Mar 12;12(3):264. doi: 10.3390/vetsci12030264.

Construction of a TAT-Cas9-EGFP Site-Specific Integration Eukaryotic Cell Line Using Efficient PEG10 Modification.

Int J Mol Sci. 2025 Feb 4;26(3):1331. doi: 10.3390/ijms26031331.

Beyond , Pharmaceutical Molecule Production in Cell-Free Systems and the Use of Noncanonical Amino Acids Therein.

Chem Rev. 2025 Feb 12;125(3):1303-1331. doi: 10.1021/acs.chemrev.4c00126. Epub 2025 Jan 22.

The 'Omics Revolution in CHO Biology: Roadmap to Improved CHO Productivity.

Methods Mol Biol. 2025;2853:119-137. doi: 10.1007/978-1-0716-4104-0_9.

Recombinant lactate-assimilating cyanobacteria reduce high-concentration culture-associated cytotoxicity in mammalian cells.

Arch Microbiol. 2024 Oct 3;206(11):425. doi: 10.1007/s00203-024-04149-3.

The United States Food and Drug Administration's Platform Technology Designation to Expedite the Development of Drugs.

Pharmaceutics. 2024 Jul 10;16(7):918. doi: 10.3390/pharmaceutics16070918.

Comparative Analysis of the Impact of Protein on Virus Retention for Different Virus Removal Filters.

Membranes (Basel). 2024 Jul 17;14(7):158. doi: 10.3390/membranes14070158.

Recombinant CHO Cell Pool Generation Using PiggyBac Transposon System.

Methods Mol Biol. 2024;2810:137-146. doi: 10.1007/978-1-0716-3878-1_9.

RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin-RGD interactions.

Cancer Med. 2024 Jan;13(2):e6800. doi: 10.1002/cam4.6800.

本文引用的文献

The special case of gene therapy pricing.

Nat Biotechnol. 2014 Sep;32(9):874-6. doi: 10.1038/nbt.3003.

Sanofi to propel inhalable insulin Afrezza into market.

Nat Biotechnol. 2014 Sep;32(9):851-2. doi: 10.1038/nbt0914-851a.

Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.

Nature. 2014 Oct 2;514(7520):47-53. doi: 10.1038/nature13777. Epub 2014 Aug 29.

Antibody-drug conjugates: current status and future directions.

Drug Discov Today. 2014 Jul;19(7):869-81. doi: 10.1016/j.drudis.2013.11.004. Epub 2013 Nov 15.

Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry.

MAbs. 2013 Sep-Oct;5(5):621-3. doi: 10.4161/mabs.25864. Epub 2013 Jul 24.

Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.

Adv Drug Deliv Rev. 2013 Jun 15;65(6):782-99. doi: 10.1016/j.addr.2012.10.005. Epub 2012 Oct 23.

Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques.

Proc Natl Acad Sci U S A. 2012 Oct 30;109(44):18030-5. doi: 10.1073/pnas.1213709109. Epub 2012 Oct 15.

Biopharmaceutical benchmarks 2010.

Nat Biotechnol. 2010 Sep;28(9):917-24. doi: 10.1038/nbt0910-917.

Single-batch production of recombinant human polyclonal antibodies.

Mol Biotechnol. 2010 Jul;45(3):257-66. doi: 10.1007/s12033-010-9270-9.

Biopharmaceutical benchmarks 2006.

Nat Biotechnol. 2006 Jul;24(7):769-76. doi: 10.1038/nbt0706-769.

Biopharmaceutical benchmarks 2014.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Biopharmaceutical benchmarks 2014.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献